Pfizer Enters vivo CAR-T Space in $2.6B Starna Deal

The Spiral, home to Pfizer’s New York headquarters, among Midtown skyscrapers

Pfizer is entering the vivo CAR-T space through a $2.6 billion deal for three preclinical programs from China’s Starna Therapeutics, according to the deal report. The programs are focused on autoimmune diseases and are currently in pre-IND development, Pfizer said in a Nov. 18 release.

The agreement gives Pfizer ex-China rights to the three programs in exchange for a $330 million upfront fee. It also includes up to $2.3 billion in milestone payments, plus royalties. Pfizer will lead clinical development outside Greater China, while retaining an option to obtain China rights later.

Pfizer Enters vivo CAR-T Space Before Clinical Trials

The three programs remain at an early stage. Pfizer said the candidates are in “pre-IND” development, placing the deal before clinical testing begins. The companies have not announced trial start dates or provided further details about the individual programs.

Gloved researcher handling sample tubes in a laboratory
Gloved researcher handling sample tubes in a laboratory. Illustrative stock photo via Pexels.

Pfizer plans to manufacture finished drug product for the early trials at its U.S. sites, according to the company. That manufacturing plan is part of the agreement’s development outline; the source did not provide a schedule for those trials or identify when a first study might begin.

The transaction marks Pfizer’s first move into in vivo CAR-T specifically. The company already has in vivo expertise in gene-editing therapy development through its collaboration with Beam Therapeutics, but the Starna agreement adds a separate set of CAR-T programs.

A Deal Spanning Autoimmune Disease and Oncology

Pfizer’s rights extend beyond autoimmune indications. The deal also gives the company rights to use the programs for oncology, though the companies did not provide more detail about that part of the arrangement. Pfizer also received an opportunity to license compounds from a separate collaboration.

Michael Vincent, Pfizer’s chief inflammation and immunology officer, described in vivo CAR-T as an emerging approach for autoimmune disease. He said patients who might benefit most are those for whom current options fall short. Vincent also cited Pfizer’s experience developing and manufacturing RNA-based medicines globally.

Starna CEO Rongkuan Hu said the company sees its targeted LNP delivery platform and RNA technology as a foundation for advancing in vivo CAR-T therapies. He described the Pfizer agreement as a way to work toward bringing therapies to patients worldwide. Those comments reflect the executives’ views; the programs remain preclinical.

Starna’s Pipeline and Pfizer’s Next Role

Jiangsu-based Starna was founded in 2021 and is developing a pipeline of mRNA therapies. The source says that pipeline includes in vivo cell therapies, therapeutic cancer vaccines and a vaccine for respiratory syncytial virus infection. Starna raised $44 million in a series B in May, backed by Lilly Asia Ventures and Primavera Capital.

Pfizer will take the lead on clinical development outside Greater China under the agreement. The companies have not disclosed additional program details, and no clinical outcomes are available from these preclinical candidates. Their next described step is development toward early trials, with Pfizer planning to use U.S. manufacturing sites for finished drug product.

The deal arrives as companies pursue cell therapy programs for cancer and autoimmune disease. Meditech Wire has covered Merck’s rare tumor treatment, an FDA draft guidance for early solid tumor trials and a lung cancer diagnostic collaboration. Those stories address other treatment and development efforts, not the Starna programs.

Pfizer’s agreement therefore sets out rights, payments and development responsibilities, while leaving the candidates at the preclinical stage. Further information about trial timing, individual programs and the separate compound collaboration has not yet been provided.

Facebook
Pinterest
LinkedIn
WhatsApp

Spencer Hulse is the Editorial Director at Grit Daily. He is responsible for overseeing other editors and writers, day-to-day operations, and covering breaking news.

Related Articles